Abstract
Note: This study was retracted by the authors in 2016 due to an inability to reproduce the results.
The original research investigated the role of eukaryotic initiation factor 6 (eIF6) in skin scarring. It proposed that eIF6 modulates M2 macrophages—immune cells central to tissue repair—to act as a "fibrosis inhibitor." The study reported that eIF6 downregulates pro-scarring factors like VEGF and TIMP-2 while promoting the matrix-degrading enzyme MMP-2.
Introduction
Cicatrization, or pathological scarring, often follows burns or trauma, leading to functional impairment. M2 macrophages are key players in the repair phase of wound healing but can become profibrotic, causing excessive extracellular matrix (ECM) deposition. Previous observations suggested eIF6 might inhibit skin fibrosis, but the underlying molecular mechanism remained unclear. This study aimed to identify target genes regulated by eIF6 in M2 macrophages.
Methods
Researchers compared wild-type ($eIF6^{+/+}$) and knockout ($eIF6^{+/-}$) C57BL/6 mice. Peritoneal macrophages were harvested and induced into the M2 phenotype using Interleukin-4 (IL-4). The phenotype was validated using flow cytometry for markers such as CD206 and F4/80 to ensure the cells were correctly polarized for the study.
Key Insights and Results
The study proposed that eIF6 mitigates scarring through a multi-pronged mechanism:
- Angiogenesis Control: eIF6 was found to downregulate Vascular Endothelial Growth Factor (VEGF), potentially preventing the overgrowth of blood vessels in hypertrophic scars.
- ECM Remodeling Balance: The authors reported that eIF6 upregulates MMP-2 (which degrades ECM) and downregulates TIMP-2 (which inhibits degradation), shifting the balance away from fibrosis.
- High Purity Induction: The M2 induction process was reported as highly successful, achieving a high degree of phenotypic consistency.
Microarray analysis of 1,716 differentially expressed genes supported these findings, showing significant differences in mRNA and protein levels of VEGF, TIMP-2, and MMP-2 between wild-type and knockout groups ($P < 0.05$).
Retraction and Limitations
The primary limitation of this work is its lack of reproducibility. Shortly after publication, the authors issued a formal retraction, stating they could not replicate the results and were unsure of the cause. While the study suggested a specific pathway for eIF6's anti-fibrotic effects, these findings currently lack experimental validation. Future research would need to confirm these pathways in in vivo models and explore the specific signaling cascades that link eIF6's translational regulation to the secretion of inflammatory mediators.
Summary updated